Trial Profile
Post-marketing Observational Study to Evaluate the Safety and Efficacy of HUMIRA® (Adalimumab SC) for the Treatment of Moderate to Severe Crohn's Disease in Daily Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 25 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 14 Aug 2015 Planned End Date changed from 1 Jun 2020 to 1 Dec 2015 as per ClinicalTrials.gov record.
- 14 Aug 2015 Planned primary completion date changed from 1 Jun 2020 to 1 Dec 2015 as per ClinicalTrials.gov record.